ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino …
ISIS Pharmaceuticals, Inc. (NYSE:ISIS) has been reiterated as a Neutral at Piper Jaffray by research analyst Joshua Schimmer in a recent report released today.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) reported pro forma operating income of $4.
In a research report issued today, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) with a price target of …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention …
The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology …
In a research report issued Monday, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) with a $68 price …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced it significantly outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance ending the …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced positive results from a Phase 1 study with ISIS-PKKRx.
